{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:40:35Z","timestamp":1787020835421,"version":"build-2736575974"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,8,9]],"date-time":"2018-08-09T00:00:00Z","timestamp":1533772800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2018,8,9]],"date-time":"2018-08-09T00:00:00Z","timestamp":1533772800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AR050880"],"award-info":[{"award-number":["AR050880"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AR052465"],"award-info":[{"award-number":["AR052465"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13075-018-1667-z","type":"journal-article","created":{"date-parts":[[2018,8,9]],"date-time":"2018-08-09T08:51:39Z","timestamp":1533804699000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial"],"prefix":"10.1186","volume":"20","author":[{"given":"Tanja Alexandra","family":"Stamm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus Peter","family":"Machold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Aletaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farideh","family":"Alasti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Lipsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Pisetsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Landewe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desiree","family":"van der Heijde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Sepriano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Aringer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitri","family":"Boumpas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd","family":"Burmester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Cutolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Ebner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winfried","family":"Graninger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Huizinga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Schett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrik","family":"Schulze-Koops","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul-Peter","family":"Tak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Martin-Mola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferdinand","family":"Breedveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef","family":"Smolen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,9]]},"reference":[{"issue":"8","key":"1667_CR1","doi-asserted-by":"publisher","first-page":"699","DOI":"10.7326\/0003-4819-124-8-199604150-00001","volume":"124","author":"A van der Heide","year":"1996","unstructured":"van der Heide A, Jacobs JW, Bijlsma JW, Heurkens AH, van Booma-Frankfort C, van der Veen MJ, Haanen HC, Hofman DM, van Albada-Kuipers GA, ter Borg EJ, et al. The effectiveness of early treatment with \u201csecond-line\u201d antirheumatic drugs. A randomized, controlled trial. Ann Intern Med. 1996;124(8):699\u2013707.","journal-title":"Ann Intern Med"},{"key":"1667_CR2","doi-asserted-by":"crossref","unstructured":"Nell VK, Machold KP, Eberl G, Stamm TA, Uffmann M, Smolen JS. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford). 2004; Epub (ahead of print)","DOI":"10.1093\/rheumatology\/keh199"},{"issue":"6","key":"1667_CR3","first-page":"446","volume":"111","author":"LR Lard","year":"2001","unstructured":"Lard LR, Visser H, Speyer I, vander Horst-Bruinsma IE, Zwinderman AH, Breedveld FC, Hazes J. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. AmJMed. 2001;111(6):446\u201351.","journal-title":"AmJMed"},{"issue":"9430","key":"1667_CR4","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S0140-6736(04)16676-2","volume":"364","author":"C Grigor","year":"2004","unstructured":"Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, Kincaid W, Porter D. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet. 2004;364(9430):263\u20139.","journal-title":"Lancet"},{"key":"1667_CR5","doi-asserted-by":"crossref","unstructured":"Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Kerstens PJ, Nielen MM, Vos K, van Schaardenburg D, Speyer I, Seys PE, Breedveld FC, Allaart CF, et al. DAS-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis. Ann Rheum Dis. 2010;69(1):65\u20139.","DOI":"10.1136\/ard.2008.097683"},{"issue":"5","key":"1667_CR6","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1002\/acr.21641","volume":"64","author":"JA Singh","year":"2012","unstructured":"Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, Moreland LW, O'Dell J, Winthrop KL, Beukelman T, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res. 2012;64(5):625\u201339.","journal-title":"Arthritis Care Res"},{"issue":"3","key":"1667_CR7","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1136\/annrheumdis-2013-204573","volume":"73","author":"JS Smolen","year":"2014","unstructured":"Smolen JS, Landewe R, Breedveld FC, Buch M, Burmester G, Dougados M, Emery P, Gaujoux-Viala C, Gossec L, Nam J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73(3):492\u2013509.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1667_CR8","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1093\/rheumatology\/kem007","volume":"46","author":"M Mierau","year":"2007","unstructured":"Mierau M, Schoels M, Gonda G, Fuchs J, Aletaha D, Smolen JS. Assessing remission in clinical practice. Rheumatology(Oxford). 2007;46(6):975\u20139.","journal-title":"Rheumatology(Oxford)"},{"issue":"3","key":"1667_CR9","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1136\/ard.2011.149765","volume":"70","author":"DT Felson","year":"2011","unstructured":"Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, Aletaha D, Allaart CF, Bathon J, Bombardieri S, et al. American College of Rheumatology\/European league against rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis. 2011;70(3):404\u201313.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"1667_CR10","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1002\/art.24433","volume":"60","author":"D Aletaha","year":"2009","unstructured":"Aletaha D, Funovits J, Breedveld FC, Sharp J, Segurado O, Smolen JS. Rheumatoid arthritis joint progression in sustained remission is determined by disease activity levels preceding the period of radiographic assessment. Arthritis Rheum. 2009;60(5):1242\u20139.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"1667_CR11","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1136\/ard.2009.121491","volume":"69","author":"Y Tanaka","year":"2010","unstructured":"Tanaka Y, Takeuchi T, Mimori T, Saito K, Nawata M, Kameda H, Nojima T, Miyasaka N, Koike T, investigators RRRs. Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study. Ann Rheum Dis. 2010;69(7):1286\u201391.","journal-title":"Ann Rheum Dis"},{"issue":"19","key":"1667_CR12","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1056\/NEJMoa1316133","volume":"371","author":"P Emery","year":"2014","unstructured":"Emery P, Hammoudeh M, FitzGerald O, Combe B, Martin-Mola E, Buch MH, Krogulec M, Williams T, Gaylord S, Pedersen R, et al. Sustained remission with etanercept tapering in early rheumatoid arthritis. N Engl J Med. 2014;371(19):1781\u201392.","journal-title":"N Engl J Med"},{"issue":"9","key":"1667_CR13","first-page":"1677","volume":"31","author":"DE Furst","year":"2004","unstructured":"Furst DE. Window of opportunity. J Rheumatol. 2004;31(9):1677\u20139.","journal-title":"J Rheumatol"},{"issue":"12","key":"1667_CR14","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1136\/annrheumdis-2012-201893","volume":"71","author":"K Raza","year":"2012","unstructured":"Raza K, Saber TP, Kvien TK, Tak PP, Gerlag DM. Timing the therapeutic window of opportunity in early rheumatoid arthritis: proposal for definitions of disease duration in clinical trials. Ann Rheum Dis. 2012;71(12):1921\u20133.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"1667_CR15","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1002\/1529-0131(199910)42:10<2184::AID-ANR20>3.0.CO;2-2","volume":"42","author":"M Green","year":"1999","unstructured":"Green M, Marzo-Ortega H, McGonagle D, Wakefield R, Proudman S, Conaghan P, Gooi J, Emery P. Persistence of mild, early inflammatory arthritis: the importance of disease duration, rheumatoid factor, and the shared epitope. Arthritis Rheum. 1999;42(10):2184\u20138.","journal-title":"Arthritis Rheum"},{"issue":"12","key":"1667_CR16","doi-asserted-by":"publisher","first-page":"3537","DOI":"10.1002\/art.27692","volume":"62","author":"MP van der Linden","year":"2010","unstructured":"van der Linden MP, le Cessie S, Raza K, van der Woude D, Knevel R, Huizinga TW, van der Helm-van Mil AH. Long-term impact of delay in assessment of patients with early arthritis. Arthritis Rheum. 2010;62(12):3537\u201346.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"1667_CR17","doi-asserted-by":"publisher","first-page":"R784","DOI":"10.1186\/ar1733","volume":"7","author":"K Raza","year":"2005","unstructured":"Raza K, Falciani F, Curnow SJ, Ross EJ, Lee CY, Akbar AN, Lord JM, Gordon C, Buckley CD, Salmon M. Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin. Arthritis Res Ther. 2005;7(4):R784\u201395.","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"1667_CR18","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1002\/art.38273","volume":"66","author":"MJ de Hair","year":"2014","unstructured":"de Hair MJ, van de Sande MG, Ramwadhdoebe TH, Hansson M, Landewe R, van der Leij C, Maas M, Serre G, van Schaardenburg D, Klareskog L, et al. Features of the synovium of individuals at risk of developing rheumatoid arthritis: implications for understanding preclinical rheumatoid arthritis. Arthritis Rheumatol. 2014;66(3):513\u201322.","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"1667_CR19","doi-asserted-by":"publisher","first-page":"406","DOI":"10.7326\/0003-4819-146-6-200703200-00005","volume":"146","author":"YP Goekoop-Ruiterman","year":"2007","unstructured":"Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, Zwinderman AH, Peeters AJ, de Jonge-Bok JM, Mallee C, et al. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med. 2007;146(6):406\u201315.","journal-title":"Ann Intern Med"},{"issue":"1","key":"1667_CR20","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/art.20712","volume":"52","author":"MA Quinn","year":"2005","unstructured":"Quinn MA, Conaghan PG, O'Connor PJ, Karim Z, Greenstein A, Brown A, Brown C, Fraser A, Jarret S, Emery P. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005;52(1):27\u201335.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"1667_CR21","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/annrheumdis-2014-206106","volume":"74","author":"P Emery","year":"2015","unstructured":"Emery P, Burmester GR, Bykerk VP, Combe BG, Furst DE, Barre E, Karyekar CS, Wong DA, Huizinga TW. Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period. Ann Rheum Dis. 2015;74(1):19\u201326.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"1667_CR22","doi-asserted-by":"publisher","first-page":"e0182751","DOI":"10.1371\/journal.pone.0182751","volume":"12","author":"IY Choi","year":"2017","unstructured":"Choi IY, Karpus ON, Turner JD, Hardie D, Marshall JL, de Hair MJ, Maijer KI, Tak PP, Raza K, Hamann J. Stromal cell markers are differentially expressed in the synovial tissue of patients with early arthritis. PLoS One. 2017;12(8):e0182751.","journal-title":"PLoS One"},{"issue":"11","key":"1667_CR23","doi-asserted-by":"publisher","first-page":"3381","DOI":"10.1002\/art.21405","volume":"52","author":"YP Goekoop-Ruiterman","year":"2005","unstructured":"Goekoop-Ruiterman YP, Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, Zwinderman AH, Ronday HK, Han KH, Westedt ML, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 2005;52(11):3381\u201390.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"1667_CR24","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1002\/art.10117","volume":"46","author":"H Visser","year":"2002","unstructured":"Visser H, le Cessie S, Vos K, Breedveld FC, Hazes JM. How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. Arthritis Rheum. 2002;46(2):357\u201365.","journal-title":"Arthritis Rheum"},{"issue":"9","key":"1667_CR25","first-page":"1580","volume":"69","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. AnnRheumDis. 2010;69(9):1580\u20138.","journal-title":"AnnRheumDis"},{"key":"1667_CR26","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/art.1780380602","volume":"38","author":"DT Felson","year":"1995","unstructured":"Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995;38:727\u201335.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"1667_CR27","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/art.1780230202","volume":"23","author":"JF Fries","year":"1980","unstructured":"Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum. 1980;23(2):137\u201345.","journal-title":"Arthritis Rheum"},{"issue":"9","key":"1667_CR28","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1002\/art.21235","volume":"52","author":"D Aletaha","year":"2005","unstructured":"Aletaha D, Ward MM, Machold KP, Nell VP, Stamm T, Smolen JS. Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. Arthritis Rheum. 2005;52(9):2625\u201336.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"1667_CR29","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/art.1780380107","volume":"38","author":"ML Prevoo","year":"1995","unstructured":"Prevoo ML, 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38(1):44\u20138.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"1667_CR30","first-page":"261","volume":"27","author":"D van der Heijde","year":"2000","unstructured":"van der Heijde D. How to read radiographs according to the sharp\/van der Heijde method. J Rheumatol. 2000;27(1):261\u20133.","journal-title":"J Rheumatol"},{"issue":"13","key":"1667_CR31","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1056\/NEJMoa1507247","volume":"374","author":"MC Genovese","year":"2016","unstructured":"Genovese MC, Kremer J, Zamani O, Ludivico C, Krogulec M, Xie L, Beattie SD, Koch AE, Cardillo TE, Rooney TP, et al. Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med. 2016;374(13):1243\u201352.","journal-title":"N Engl J Med"},{"issue":"3","key":"1667_CR32","first-page":"495","volume":"69","author":"KP Machold","year":"2010","unstructured":"Machold KP, Landewe R, Smolen JS, Stamm TA, van der Heijde DM, Verpoort KN, Brickmann K, Vazquez-Mellado J, Karateev DE, Breedveld FC, et al. The stop arthritis very early (SAVE) trial, an international multicentre, randomised, double-blind, placebo-controlled trial on glucocorticoids in very early arthritis. AnnRheumDis. 2010;69(3):495\u2013502.","journal-title":"AnnRheumDis"},{"issue":"5","key":"1667_CR33","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/nrrheum.2015.8","volume":"11","author":"JS Smolen","year":"2015","unstructured":"Smolen JS, Aletaha D. Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges. Nat Rev Rheumatol. 2015;11(5):276\u201389.","journal-title":"Nat Rev Rheumatol"},{"issue":"9636","key":"1667_CR34","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S0140-6736(08)61000-4","volume":"372","author":"P Emery","year":"2008","unstructured":"Emery P, Breedveld FC, Hall S, Durez P, Chang DJ, Robertson D, Singh A, Pedersen RD, Koenig AS, Freundlich B. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet. 2008;372(9636):375\u201382.","journal-title":"Lancet"},{"issue":"3","key":"1667_CR35","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315\u201324.","journal-title":"Arthritis Rheum"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-018-1667-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13075-018-1667-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-018-1667-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T09:58:08Z","timestamp":1589536688000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-018-1667-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,9]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1667"],"URL":"https:\/\/doi.org\/10.1186\/s13075-018-1667-z","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,9]]},"assertion":[{"value":"16 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The EudraCT number is 2006\u2013002787-26 and the protocol number from the ethical committee of the Medical University of Vienna, Austria, that first approved the protocol is 292\/2006. Ethical committees of each institution approved the study and all patients gave written informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The present manuscript does not contain any individual person\u2019s data, such as individual details, images, or videos.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"TAS has received speaker fees from AbbVie, Janssen, MSD, Novartis, and Roche and grant support from AbbVie. MAS has received speaker fees from MSD. KPM has received money from AbbVie (speaker\u2019s fees, consulting fees, research grant), Astro (speaker\u2019s fees, consulting fees), Baxter (consulting fees), BMS (speaker\u2019s fees), Celgene (speaker\u2019s fees), Janssen-Cilag (speaker\u2019s fees), Lilly (speaker\u2019s fees), MSD (speaker\u2019s fees), Novartis (speaker\u2019s fees, consulting fees), Pfizer (speaker\u2019s fees), Roche (speaker\u2019s fees), UCB (speaker\u2019s fees), Arsanis (consulting fees), and Sandoz (speaker\u2019s fees). DA has served as a consultant for and\/or received grant\/research support from AbbVie, Pfizer, Gr\u00fcnenthal, Merck Medac, UCB, Mitsubishi\/Tanabe, Janssen, and Roche. PL received consulting fees from Janssen, EMD Serono, Astra Zeneca, UCB, Roche, Celgene, Sanofi, and Horizon, but none of them relates to the content of this manuscript. RL has received fees for consultation or participation in advisory boards by Abbott\/AbbVie, Ablynx, Amgen, Astra-Zeneca, Bristol Myers Squibb, Celgene, Janssen (formerly Centocor), Galapagos, Glaxo-Smith-Kline, Novartis, Novo-Nordisk, Merck, Pfizer, Roche, Schering-Plough, TiGenix, UCB, and Wyeth; research grants from Abbott, Amgen, Centocor, Novartis, Pfizer, Roche, Schering-Plough, UCB and Wyeth and speaker fees from Abbott\/AbbVie, Amgen, Bristol Myers Squibb, Janssen (formerly Centocor), Merck, Pfizer, Roche, Schering-Plough, UCB, and Wyeth; furthermore, RL is director of Rheumatology Consultancy BV which is a registered company under Dutch law. DvdH has received consulting fees from AbbVie, Amgen, Astellas, AstraZeneca, BMS, Boeringer Ingelheim, Celgene, Daiichi, Eli-Lilly, Galapagos, Gilead, Janssen, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi, and UCB and is director of Imaging Rheumatology BV. MA has received advisory Boards and\/or speaking fees from AbbVie, Astra Zeneca, BMS, Chugai, GSK, Hexal, Lilly, MSD, Novartis, Pfizer, Roche, Sanofi, and UCB; his institution is clinical trial site for AbbVie, Astra Zeneca, Boehringer Ingelheim, Novartis, Pfizer, and Roche. GB has received speaker fees from MSD, UCB and Roche and research funds from AbbVie, BMS, UCB, and Roche. MC has received speaker fees from Biogen, Mundipharm, Pfizer and Menarini and research funds from BMS, Horizon, Actelion, Celgene, and MSD. WE has received consulting fees from Novartis and Abbvie. TH has received lecture fees\/consultancy fees from Merck, UCB, Bristol Myers Squibb, Biotest AG, Pfizer, GSK, Novartis, Roche, Sanofi-Aventis, Abbott, Crescendo Bioscience, Nycomed, Boeringher, Takeda, Epirus, and Eli Lilly. GS has received speaker fees from BMS, Celgene, Chugai, Lilly, Roche, and UCB. HSK has received speaker fees from AbbVie, Actelion, AstraZeneca, Biogen International, Boehringer Ingelheim, BMS, Celgene, Celltrion, Chugai, Cinfa Biotech, GSK, Hospira, Janssen-Cilag, Lilly, MSD, Medac, Merck, Mundipharma, Novartis, Pfizer, Hexal Sandoz, Roche, and UCB. PPT has become an employee of GlaxoSmithKline. GSK has not been involved in this study. JS has received grants for his institution from Abbvie, Lilly, MSD, Pfizer and Roche and has provided remunerated expert advice to and\/or had speaking engagements for Abbvie, Amgen, Astra-Zeneca, Astro, BMS, Boehringer-Ingelheim, Celgene, Celltrion, Chugai, Gilead, Glaxo, ILTOO, Janssen, Lilly, Medimmune, MSD, Novartis-Sandoz, Pfizer, Roche, Samsung, Sanofi, and UCB. The remaining authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"174"}}